BridgeBio develops drugs for genetic diseases, led by heart drug Attruby.
BridgeBio Pharma, Inc. (BBIO) is expected to report earnings on Wednesday, November 4, 2026, after the close. Estimated release time 16:04 ET. Consensus EPS estimate is $-0.56.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-10 | Jun 2026 qtr | $-0.58 | $-0.78 | — | $243.68M |
| 2026-05-07 | Mar 2026 qtr | $-0.68 | $-0.84 | — | $194.51M |
| 2026-02-24 | Dec 2025 qtr | $-0.71 | $-1.00 | — | $154.18M |
| 2025-10-29 | Sep 2025 qtr | $-0.88 | $-0.95 | -8.0% | $120.70M |
| 2025-08-05 | Jun 2025 qtr | $-0.83 | $-0.95 | — | $110.56M |
| 2025-04-29 | Mar 2025 qtr | $-1.00 | $-0.88 | +12.0% | $116.63M |
| 2025-02-20 | Dec 2024 qtr | $-1.09 | $-1.31 | — | $5.88M |
| 2024-08-01 | Jun 2024 qtr | $-1.09 | $-1.02 | +6.4% | $2.17M |
BBIO has beaten consensus EPS in 2 of its last 3 scored quarters.
See BBIO on the live calendar →